糖尿病肾病肠道菌群治疗的研究进展  

Research progress in the treatment of intestinal flora in diabetic nephropathy

作　　者：冯一卓 李青霞 刘雪倩 白璐[1] 曲卓敏 刘若琪 赵凌霞[1] Feng Yizhuo;Li Qingxia;Liu Xueqian;Bai Lu;Qu Zhuomin;Liu Ruoqi;Zhao Lingxia(Department of Endocrinology,the Third Hospital of Shanxi Medical University,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Taiyuan 030032,China)

机构地区：[1]山西医科大学第三医院(山西白求恩医院山西医学科学院同济山西医院)内分泌科,太原030032

出　　处：《中国医师杂志》2024年第11期1753-1757,共5页Journal of Chinese Physician

基　　金：山西省基础研究计划(202103021224356);山西省重点研发计划(国际科技合作)(201903D421067)。

摘　　要：糖尿病肾病(DN)是以持续蛋白尿和肾功能进行性下降为特征的临床综合征,是糖尿病微血管并发症之一。随着对DN发病机制的深入了解,临床发现了肠道菌群失调在该疾病中的作用。这表明,恢复宿主健康的肠道菌群可能是改善DN的一种手段。事实上,最近的研究表明,许多目前用于治疗DN的药物会影响肠道菌群组成。本综述将肠道菌群视为DN发展的主要影响因素之一,总结了针对肠道菌群的DN疗法,为DN的诊治提供新思路。Diabetic nephropathy(DN)is a clinical syndrome characterized by persistent proteinuria and progressive decline in renal function,and is one of the microvascular complications of diabetes.With the in-depth understanding of the pathogenesis of DN,the role of intestinal flora imbalance in the disease has been found clinically.This suggests that restoring the host's healthy gut flora may be a means of improving DN.In fact,recent studies have shown that many of the drugs currently used to treat DN affect gut microbiota composition.In this review,intestinal flora is regarded as one of the main factors affecting the development of DN,and DN therapy targeting intestinal flora is summarized to provide new ideas for the diagnosis and treatment of DN.

关 键 词：糖尿病肾病 肠道菌群 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]